M PHARMACEUTICAL INC. TO REMOVE PARABENS FROM ALL FUTURE PRODUCTS
(firmenpresse) - M PHARMACEUTICAL INC. TO REMOVE PARABENS FROM ALL FUTURE PRODUCTS
VANCOUVER, B.C., CANADA (January 19, 2017) - M Pharmaceutical Inc. (CSE: MQ, OTCQB: MPHMF, FWB: T3F2), (the "Company" or M Pharma), announced today as part of its planned acquisition of Cincinnati based 40 Js, that it will immediately transition all products to paraben-free formulations based on an exclusive license it is acquiring for an innovative, patent pending paraben free technology.
Parabens are a class of preservatives widely used in cosmetic and pharmaceutical products. They have been included in 85% of cosmetic products since the 1950s to prevent bacterial and fungal growth and increase shelf life, said Gary Thompson, President and CEO of M Pharmaceutical USA. There is a growing concern with parabens, as they have been shown to disrupt hormone function, an effect that is linked to an increased risk of certain cancers and reproductive issues. In 2012 the European Union banned the use of some parabens; however, here in the US, the FDA and scientists have not yet weighed in on the new research on the safety of parabens. Many retailers are not waiting on the FDA and are taking proactive steps in moving towards phasing out the sale of products that include parabens, said Thompson.
We are taking a two phase approach to maximizing this new proprietary technology for replacing parabens. Phase one will be to formulate all M Pharmaceutical products to include this new parabens free technology. This will be implemented immediately following the closing of the 40Js acquisition. Phase two will be actively out-licensing this proprietary technology to other manufacturers seeking solutions to providing paraben free products to their customers, said Mr. Thompson.
Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to its recent acquisition of C-103, a reformulation of orlistat from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights. The Company has also recently acquired an FDA cleared fertility product branded as ToConceive that represents its first offering in the women's health field.
M Pharma trades on the Canadian Securities Exchange (CSE) under the ticker symbol MQ as well as on the OTCQB as MPHMF and FWB (Frankfurt Stock Exchange) as T3F2.
For more information contact:
Investor Relations
Phone: +1 604 428 0511
info(at)m-pharma.ca
www.m-pharma.ca
Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval, commercialization of the rights to the Companys biomedical & drug technologies, and acquisition of new products. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Companys filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.
Notice regarding investigational devices: C-103 and Trimeo are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.
Leseranfragen:
" alt="Pershing Gold to Present at Vancouver Resource Investment Conference
Datum: 19.01.2017 - 13:03 Uhr
Sprache: Deutsch
News-ID 518670
Anzahl Zeichen: 4594
contact information:
Town:
Wien
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 248 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"M PHARMACEUTICAL INC. TO REMOVE PARABENS FROM ALL FUTURE PRODUCTS
"
steht unter der journalistisch-redaktionellen Verantwortung von
M Pharmaceutical Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
